CAR-T cell therapy in China
This is not a diagnosis. It only helps you find relevant information.
What China offers
China's NMPA has approved at least eight CAR-T products since 2021, including satri-cel in June 2026, the first CAR-T approved for a solid tumor. Two (axi-cel and cilta-cel) are also FDA-approved. Access is through hospital hematology or oncology teams, often via international departments, or through clinical trials.
465 clinical trials are recruiting at sites in China (ClinicalTrials.gov, 2026-10-26). See the trials
Read more about car-t cell therapyHospitals for this
NanjingTaikang Xianlin Drum Tower Hospital泰康仙林鼓楼医院International deptVerified
ShanghaiRuijin Hospital, Shanghai Jiao Tong University School of Medicine上海交通大学医学院附属瑞金医院International deptVerified
ShanghaiShanghai Jiahui International Hospital上海嘉会国际医院International deptJCIVerified
HangzhouThe First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU)浙江大学医学院附属第一医院International deptVerified
NanjingNanjing Drum Tower Hospital南京鼓楼医院No public intl deptReported
Patients like you
News
New Zealand man becomes first foreign patient to receive solid-tumor CAR-T in ChinaNew Zealand · 2026 · News · ≈$139,436.62
News
New Zealand CAR-T patient in Shanghai: total journey reported around USD 65,0002026 · News · ≈$65,000
Hospital photoNewsNew Zealand myeloma patient joins a CAR-T trial in Shanghai for about $65,000 including airfareNew Zealand · 2025 · News · ≈$65,000
Your next steps
- Get your records and scans translated into Chinese.
- Contact the international department of one or two hospitals above.
- Check your visa. Many travelers qualify for visa-free entry or transit.
- Plan follow-up care with your doctor at home before you go.